- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02404012
Iron Supplement to Improve Iron Status Following Bariatric Surgery
Comparison of Iron Supplement Formulations to Improve Iron Status Following Roux-en-Y and Sleeve Gastrectomy Bariatric Surgery
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Objectives:
To determine the most effective oral iron supplementation regimen for repletion of iron deficiency in patients who have had gastric bypass or sleeve gastrectomy. In iron deficient patients, two supplement regimens will be compared:
- Ferrous sulfate 65 mg t.i.d. (standard of care / control), which is elemental iron
- AspironTM, which is an organic formulation of iron
Primary outcomes will be reference indices of iron status:
- Ferritin, TIBC, sTfR, and sTfR:ferritin ratio
- Secondary outcomes will be:
- measures of anemia, determined by blood hemoglobin concentrations
- measures of cognitive function via several computerized tests on working memory, sustained attention, and spatial memory
- fatigue by Multidimensional Fatigue Inventory questionnaire
- Quality of life by SF-36 Survey
Safety outcomes will be:
• adverse events, compliance, measures of iron toxicity, and liver enzymes
- In the same subjects undergoing iron supplementation described in Aim 1, to determine the contribution of dietary factors (including heme and non-heme iron intake, and intake of enhancers and inhibitors of iron absorption) to changes in iron status.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Indiana
-
West Lafayette, Indiana, United States, 47906
- Purdue University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject has a history of RYGB or SG weight loss surgery at least 6 months ago
- Subject meets at least 2 of the 4 previously mentioned conditions classifying them as iron deficient
- Subject is female
- Subject is at least 18 but not more than 65 years of age (post-menopausal status is an exclusion criteria)
- Subject has signed an informed consent.
Exclusion Criteria:
- Subject is pregnant
- Subject has history of surgical revision or conversion of bariatric procedure
- Subject is under a treatment regimen that requires iron supplementation greater than standard of care
- Subject has had parenteral iron less than one month before screening visit
- Subject has extremely heavy menstruation
- Subject has a history of hospitalization for acute illness in the previous 3 months
- Subject has current active malignant neoplasm; or history of malignancy other than localized basal cell cancer of skin during previous 5 years
- Subject has gastrointestinal disease that involve increased inflammation or blood loss (e.g. Crohn's disease, Ulcerative colitis)
- Subject is post-menopausal
- Subject has severe anemia, with a hemoglobin > 7.0 g/dL (subjects will be notified of their results)
- Subject is taking an erythropoietin stimulating medication or is on hemodialysis.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Ferrous sulfate
Ferrous sulfate 65 mg.
t.i.d is the standard of care for oral supplementation for iron deficiency
|
Participants will be provided supplementation for 8 weeks
|
Experimental: AspironTM 65 mg t.i.d.
AspironTM, an organic formulation of iron, is the experimental treatment for oral supplementation of iron deficiency
|
Participants will be provided supplementation for 8 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Iron status
Time Frame: 8 weeks
|
Ferritin, TIBC, sTfR
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Anemia assessed by Hemoglobin concentrations
Time Frame: 8 weeks
|
8 weeks
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety outcomes assessed by adverse events, compliance
Time Frame: 8 weeks
|
8 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB1410015305
Plan for Individual participant data (IPD)
Study Data/Documents
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Anemia, Iron Deficiency
-
Pennington Biomedical Research CenterRecruitingIron-deficiency | Iron Deficiency Anemia | Iron Deficiency Anemia TreatmentUnited States
-
Children's Hospital Los AngelesNot yet recruitingAnemia | Iron Deficiency Anemia | Anemia, Iron Deficiency | IDA - Iron Deficiency AnemiaUnited States
-
King's CollegeCompletedIron-deficiency | Iron Deficiency Anemia | Iron Deficiency (Without Anemia)United States
-
Arrowhead Regional Medical CenterRecruitingIron Deficiency Anemia of PregnancyUnited States
-
Luzerner KantonsspitalRecruitingIron Deficiency Anemia | Iron Deficiency Anemia Treatment | Iron DeficienciesSwitzerland
-
Swiss Federal Institute of TechnologyUnited States Agency for International Development (USAID); Quadram Institute... and other collaboratorsCompletedIron-deficiency | Iron Deficiency Anemia | Iron Deficiency (Without Anemia)Peru
-
Children's Hospital Los AngelesWithdrawnAnemia | Iron-deficiency Anemia | Healthy ControlsUnited States
-
Baylor College of MedicineNational Heart, Lung, and Blood Institute (NHLBI)CompletedIron-deficiency | Iron Deficiency AnemiaUnited States
-
Iowa State UniversityCompletedIron-deficiency | Iron Deficiency Anemia | Iron Deficiency Anemia Treatment | Iron Deficiency Anaemia Due to Dietary CausesUnited States
-
Société des Produits Nestlé (SPN)CompletedIron-deficiency | Anemia | Iron Deficiency AnemiaPhilippines
Clinical Trials on Oral iron supplementation
-
University of PecsNot yet recruitingAnemia | GastroIntestinal BleedingHungary
-
Prof Simon KaranjaUniversity of Oxford; Swiss Federal Institute of TechnologyRecruitingIron Deficiency AnemiaKenya
-
Icahn School of Medicine at Mount SinaiCompletedIron Deficiency AnemiaUnited States
-
University of South FloridaNational Heart, Lung, and Blood Institute (NHLBI)RecruitingVery Low Birth Weight Infant | Anemia of PrematurityUnited States
-
Nadirah Rasyid RidhaHasanuddin UniversityCompletedIron Deficiency, Anaemia in ChildrenIndonesia
-
University of MinnesotaNational Heart, Lung, and Blood Institute (NHLBI); Syracuse University; Liverpool... and other collaboratorsCompletedIron-deficiency | Iron-deficiency AnemiaGhana
-
Eli Lilly and CompanyCompleted
-
Biocruces Bizkaia Health Research InstituteSociedad Espanola de Angiologia y Cirugia VascularRecruitingAnemia | Peripheral Arterial Occlusive DiseaseSpain
-
University of Alabama at BirminghamRecruitingTiming of Sodium Intake and Nocturnal Sodium Excretion and Blood Pressure in Obese African AmericansHypertension | Obesity | Salt; Excess | Circadian DysregulationUnited States
-
Milton S. Hershey Medical CenterCompleted